Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 34.85 +2.80 (+8.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,304,706 Open 32.14 Bid (Size) 34.81 (1) Ask (Size) 36.00 (5) Prev. Close 32.05 Today's Range 32.00 - 35.42 52wk Range 23.14 - 35.56 Shares Outstanding 38,297,975 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday June 18, 2024 Via Benzinga Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga Performance YTD +16.09% +16.09% 1 Month +40.75% +40.75% 3 Month +33.32% +33.32% 6 Month +15.21% +15.21% 1 Year +33.99% +33.99% More News Read More 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Analyst Ratings For Mirum Pharmaceuticals May 09, 2024 Via Benzinga Analyst Ratings For Mirum Pharmaceuticals April 17, 2024 Via Benzinga Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies June 17, 2024 Via Benzinga Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday June 17, 2024 Via Benzinga Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies June 17, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 June 16, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress June 06, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older May 31, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress May 29, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting May 18, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference May 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC May 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 May 01, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome April 02, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying March 28, 2024 Via Benzinga Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
